New Products Are Expected to Be Introduced to the Cancer Vaccine Market over the Next Five Years.

[Guest guest]

New Products Are Expected to Be Introduced to the Cancer Vaccine Market

over the Next Five Years.

DUBLIN, Ireland--(BUSINESS WIRE)--Jan 4, 2006 - Research and Markets

(http://www.researchandmarkets.com/reports/c30125) has announced the

addition of the Espicom Business Intelligence Ltd report Cancer Vaccine

Developments To 2011 to their offering.

After years of promise, the cancer vaccine market is on the verge of

huge growth - if it can overcome the clinical, regulatory and

pharmacoeconomic obstacles.

With a number of product launches expected over the next five years,

this insightful market report takes a balanced view of the players and

products that will shape this much awaited market sector.

With two cancer vaccines already launched, M-Vax in Switzerland and

OncoVAX in Switzerland and the Netherlands, industry and investor

interest is increasingly looking at the significant number of cancer

vaccines charging down the Phase II/III pipeline. Even though more than

half the 105 products in late-stage research will fail to make it to

registration, the next five years will see a number of novel drug

launches in a range of key cancers such as melanoma and those of the

lung, breast and prostate.

But key issues remain...

http://www.pharmalive.com/News/index.cfm?articleid=303105 & categoryid=10

Kathy Meade

Arlington Educational Consulting

http://www.vapcacoalition.org/

http://www.naspcc.org/

phone

fax

So much has been said and sung of beautiful young girls, why don't

somebody wake up to the beauty of old women?

Harriet Beecher Stowe